Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company dedicated to developing and commercializing therapies for the preservation of vision. Their primary focus is on ONS-5010/LYTENAVA™, an ophthalmic formulation of bevacizumab, which is intended to be the first FDA-approved treatment for wet age-related macular degeneration (wet AMD), as well as other retinal diseases like diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). They are committed to providing a safer and more cost-effective alternative to the currently used unapproved repackaged intravenous (IV) bevacizumab.

The company has achieved significant milestones in its development, including regulatory approval in the European Union and the United Kingdom for LYTENAVA™ as a treatment for wet AMD. They are currently working to launch the drug commercially in these regions and are also conducting a non-inferiority study in the United States to potentially resubmit a Biologics License Application (BLA) to the FDA for approval of ONS-5010/LYTENAVA™ for wet AMD treatment.

Outlook Therapeutics doesn't explicitly mention job flexibility on their website or job postings. Therefore, it is impossible to determine the company's stance on remote work, flexible schedules, or other forms of job flexibility.

Outlook Therapeutics is a biopharmaceutical company committed to developing innovative therapies for the preservation of vision. They are focused on achieving FDA approval for ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Outlook Therapeutics aims to replace the current reliance on unapproved repackaged IV bevacizumab from compounding pharmacies with their safe and effective ophthalmic formulation, ultimately providing a viable treatment option for patients worldwide.

Outlook Therapeutics promotes a culture focused on innovation and collaboration, driven by a shared passion for developing vision-preserving therapies. The company emphasizes the importance of skill and experience in their team, highlighting the expertise they bring to tackling the challenges of mAb development. This dedication to excellence is evident in their pursuit of FDA approval for their ophthalmic formulation of bevacizumab, with the goal of providing a safer and more cost-effective treatment option for patients.

Outlook Therapeutics, Inc. does not explicitly mention a company-wide approach to diversity, equity, and inclusion on their website. They do, however, disclose information about the composition of their Board of Directors, highlighting the number of female, male, and non-binary members. This disclosure suggests that they recognize the importance of board diversity but do not explicitly outline a broader DEI strategy for the company.